Skip to main content

Interleukin-26 is a promising biomarker of sepsis but is it always reliable?

The Original Article was published on 29 August 2019

We read with interest the recent article by Tu et al. concluding that interleukin-26 (IL-26) is a better predictor of 28-day mortality in septic patients when compared with C-reactive protein (CRP) and procalcitonin (PCT) [1]. However, SOFA score remains the best predictor by far over IL-26. While we applaud the results of this study, we would like to make some comments. IL-26 is the most recently identified member of the IL-20 cytokine subfamily and is a promising mediator of inflammation overexpressed in activated or transformed T cells [2]. IL-26 has a molecular weight ranging between 19 and 36 kDa. Nearly half of critically ill patients especially those with septic shock have or develop acute kidney injury (AKI), and 20–25% will need renal replacement therapy (RRT) within the first week of their stay [3]. Out of the 52 septic patients in this study, several patients will develop AKI and necessitate continuous RRT (CRRT) [1]. The serum for IL-26 was taken on admission in the intensive care unit (ICU) in this study, and nothing can be said about the reliability of the admission level. Nevertheless, we would like to warn the clinician about daily monitoring of IL-26 like for CRP and PCT. CRRT is performed using membranes that have a cutoff value of 35–40 kDa, and therefore, some quantity of IL-26 will be eliminated by CRRT [4]. New highly adsorptive membranes (HAM) that can adsorb many molecules with a molecular weight above 35 kDa will even increase this removal [5]. This can mislead patient prognostication by artificially decreasing IL-26, but no studies have challenged this issue yet. Such studies should be done as there is already a long list of biomarkers in sepsis that are lacking reliability during CRRT [5]. To date, no single sepsis biomarker can be reliable during CRRT. While admission levels of IL-26 might be a good marker of severity and mortality of sepsis, this might not be the case for septic shock under CRRT [4, 5].

Availability of data and materials

Not applicable.

Abbreviations

IL-26:

Interleukin-26

CRP:

C-reactive protein

PCT:

Procalcitonin

AKI:

Acute kidney injury

RRT:

Renal replacement therapy

CRRT:

Continuous renal replacement therapy

HAM:

Highly adsorptive membranes

References

  1. Tu H, Lai X, Li J, Huang L, Liu Y, Cao J. Interleukin-26 is overexpressed in human sepsis and contributes to inflammation, organ injury, and mortality in murine sepsis. Crit Care. 2019;23(1):290. https://0-doi-org.brum.beds.ac.uk/10.1186/s13054-019-2574-7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Larochette V, Miot C, Poli C, Beaumont E, Roingeard P, Fickenscher H, et al. IL-26, a cytokine with roles in extracellular DNA-induced inflammation and microbial defense. Front Immunol. 2019;10:204. https://0-doi-org.brum.beds.ac.uk/10.3389/fimmu.2019.00204 eCollection 2019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Peters E, Antonelli M, Wittebole X, Nanchal R, François B, Sakr Y, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit. Crit Care. 2018;22(1):188. https://0-doi-org.brum.beds.ac.uk/10.1186/s13054-018-2112-z.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Honoré PM, Jacobs R, De Waele E, Van Gorp V, Spapen HD. Evaluating sepsis during continuous dialysis: are biomarkers still valid? Blood Purif. 2014;38(2):104–5. https://0-doi-org.brum.beds.ac.uk/10.1159/000363497 Epub 2014 Oct 17.

    Article  PubMed  Google Scholar 

  5. Honoré PM, De Bels D, Spapen HD. An update on membranes and cartridges for extracorporeal blood purification in sepsis and septic shock. Curr Opin Crit Care. 2018;24(6):463–8. https://0-doi-org.brum.beds.ac.uk/10.1097/MCC.0000000000000542 Review.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

PMH and DDB designed the paper. All authors participated in drafting and reviewing. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Patrick M. Honore.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This comment refers to the article available at https://0-doi-org.brum.beds.ac.uk/10.1186/s13054-019-2574-7.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Honore, P.M., Mugisha, A., Barreto Gutierrez, L. et al. Interleukin-26 is a promising biomarker of sepsis but is it always reliable?. Crit Care 23, 397 (2019). https://0-doi-org.brum.beds.ac.uk/10.1186/s13054-019-2691-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13054-019-2691-3